The endogenous cannabinoid receptor agonist anandamide impairs memory in rats
Behavioural Pharmacology, 7, 276-284.
Mallet, P.E. & Beninger, R.J.
published: 1996 | Research publication | Journal article
Abstract: Anandamide recently was discovered to be an endogenous substance that acts as an agonist at cannabinoid receptors in the central nervous system. Because exogenous cannabinoids such as ∆9-tetrahydrocannabinol (∆9–THC), the principle psychoactive ingredient of marijuana, have been found to impair memory, we undertook the present study to examine the mnemonic effects of anandamide. Memory was assessed in rats well-trained in a two-component instrumental discrimination task with a conditional discrimination to test reference memory and a delayed nonmatch-to-position to test working memory. Since anandamide has a short metabolic half-life, we examined the mnemonic effects of anandamide (0.0-2.0 mg/kg) in rats pre-treated with the protease inhibitor phenylmethylsulfonyl fluoride (2.0 mg/kg), serving to increase the metabolic half-life of anandamide. Under these conditions, a dose-dependent impairment of the nonmatch-to-position, but not the conditional discrimination component was found, closely resembling that observed following ∆9–THC. This is the first report that anandamide impairs memory; results suggest that endogenous cannabinoids may be involved in cognitive processes influencing memory.
Download: PDF (1.14MB) Mallet_et_al_1996.pdf
revised Jan 24/06
View all Paul Mallet documents